March 4, 2025 About this event
This event is put on by the Canadian Drug Agency
In support of the Government of Canada’s National Strategy for Drugs for Rare Diseases, Canada’s Drug Agency established a Newborn Screening Advisory Panel to develop pan-Canadian guidance for decision-makers about newborn screening. Join Dr. Hilary Vallance and Whitney Ayoub-Goulstone, cochairs of our Newborn Screening Advisory Panel, as they discuss highlights from the input received on a discussion paper outlining the proposed guidance for newborn screening across Canada.
The upcoming session will provide interested parties with an overview of the input received through our engagement activities and how it informed the advisory panel’s recommendations (final recommendations to be published in the spring of 2025). Additional information about the advisory panel and its work is available on the CDA-AMC website.